RESUMO
Adenosine A2A receptor (A2AR) antagonists have emerged as complementary non-dopaminergic drugs to alleviate Parkinson's disease (PD) symptomatology. Here, we characterize a novel non-xhantine non-furan A2AR antagonist, PBF509, as a potential pro-dopaminergic drug for PD management. First, PBF509 was shown to be a highly potent ligand at the human A2AR, since it antagonized A2AR agonist-mediated cAMP accumulation and impedance responses with KB values of 72.8 ± 17.4 and 8.2 ± 4.2 nM, respectively. Notably, these results validated our new A2AR-based label-free assay as a robust and sensitive approach to characterize A2AR ligands. Next, we evaluated the efficacy of PBF509 reversing motor impairments in several rat models of movement disorders, including catalepsy, tremor, and hemiparkinsonism. Thus, PBF509 (orally) antagonized haloperidol-mediated catalepsy, reduced pilocarpine-induced tremulous jaw movements and potentiated the number of contralateral rotations induced by L-3,4-dihydroxyphenylalanine (L-DOPA) in unilaterally 6-OHDA-lesioned rats. Moreover, PBF509 (3 mg/kg) inhibited L-DOPA-induced dyskinesia (LID), showing not only its efficacy on reversing parkinsonian motor impairments but also acting as antidyskinetic agent. Overall, here we describe a new orally selective A2AR antagonist with potential utility for PD treatment, and for some of the side effects associated to the current pharmacotherapy (i.e., dyskinesia).
RESUMO
Guanosine (GUO) is a guanine-based purine nucleoside with important trophic functions and promising neuroprotective properties. Although the neuroprotective effects of GUO have been corroborated in cellular models of Parkinson's disease (PD), its efficacy as an antiparkinsonian agent has not been fully explored in PD animal models. Accordingly, we evaluated the effectiveness of GUO in reversing motor impairments in several rodent movement disorder models, including catalepsy, tremor, and hemiparkinsonism. Our results showed that orally administered GUO antagonized reserpine-mediated catalepsy, reduced reserpine-induced tremulous jaw movements, and potentiated the number of contralateral rotations induced by L-3,4-dihydroxyphenylalanine in unilaterally 6-hydroxidopamine-lesioned rats. In addition, at 5 and 7.5 mg/kg, GUO inhibited L-DOPA-induced dyskinesia in rats chronically treated with a pro-dopaminergic agent. Overall, we describe the therapeutic potential of GUO, which may be effective not only for reversing parkinsonian motor impairments but also for reducing dyskinesia induced by treatment for PD.
RESUMO
Adenosine A2A receptor (A2AR) is a G protein-coupled receptor enriched in the striatum for which an increased expression has been demonstrated in certain neurological diseases. Interestingly, previous in vitro studies demonstrated that A2AR expression levels are reduced after treatment with S-adenosyl-L-methionine (SAM), a methyl donor molecule involved in the methylation of important biological structures such as DNA, proteins, and lipids. However, the in vivo effects of SAM treatment on A2AR expression are still obscure. Here, we demonstrated that 2 weeks of SAM treatment produced a significant reduction in the rat striatal A2AR messenger RNA (mRNA) and protein content as well as A2AR-mediated signaling. Furthermore, when the content of 5-methylcytosine levels in the 5'UTR region of ADORA2A was analyzed, this was significantly increased in the striatum of SAM-treated animals; thus, an unambiguous correlation between SAM-mediated methylation and striatal A2AR expression could be established. Overall, we concluded that striatal A2AR functionality can be controlled by SAM treatment, an issue that might be relevant for the management of these neurological conditions that course with increased A2AR expression.
Assuntos
Corpo Estriado/metabolismo , Receptor A2A de Adenosina/biossíntese , S-Adenosilmetionina/farmacologia , Animais , Corpo Estriado/efeitos dos fármacos , Metilação/efeitos dos fármacos , Ratos , Ratos Sprague-DawleyRESUMO
The molecular interaction between adenosine A2A and dopamine D2 receptors (A2ARs and D2Rs, respectively) within an oligomeric complex has been postulated to play a pivotal role in the adenosine-dopamine interplay in the central nervous system, in both normal and pathological conditions (e.g. Parkinson's disease). While the effects of A2AR challenge on D2R functioning have been largely studied, the reverse condition is still unexplored, a fact that might have impact in therapeutics. Here, we aimed to examine in a real-time mode the D2R-mediated allosteric modulation of A2AR binding when an A2AR/D2R oligomer is established. Thus, we synthesized fluorescent A2AR agonists and evaluated, by means of a flow cytometry homogeneous no-wash assay and a real-time fluorescence resonance energy transfer (FRET)-based approach, the effects on A2AR binding of distinct antiparkinsonian drugs in current clinical use (i.e. pramipexole, rotigotine and apomorphine). Our results provided evidence for the existence of a differential D2R-mediated negative allosteric modulation on A2AR agonist binding that was oligomer-formation dependent, and with apomorphine being the best antiparkinsonian drug attenuating A2AR agonist binding. Overall, the here-developed methods were found valid to explore the ability of drugs acting on D2Rs to modulate A2AR binding, thus serving to facilitate the preliminary selection of D2R-like candidate drugs in the management of Parkinson's disease.
Assuntos
Agonistas do Receptor A2 de Adenosina/metabolismo , Biopolímeros/metabolismo , Receptor A2A de Adenosina/metabolismo , Receptores de Dopamina D2/fisiologia , Citometria de Fluxo , Transferência Ressonante de Energia de Fluorescência , Células HEK293 , Humanos , Ligação Proteica , Receptores de Dopamina D2/metabolismoRESUMO
Nowadays the pharmacological treatment of the attention deficit hyperactivity disorder (ADHD) is based on amphetamine derivatives (i.e. methylphenidate). However, these drugs induce a large array of adverse side effects, thus less aggressive psychostimulant drugs (i.e. caffeine) are being proposed in the management of ADHD. Following this tendency, we decided to study the possible therapeutic use of caffeine in an animal model of ADHD, namely the neonatal 6-hydroxy-dopamine (6-OHDA)-lesioned rat. Therefore, at postnatal day 7 rats were lesioned at the left striatum with 6-OHDA or with saline. Thereafter, at postnatal day 25 their activity and attention were measured with the Olton maze before caffeine was administered ad libitum in the drinking water. Next, after 14 days of caffeine treatment, we repeated these measurements to assess the effect of caffeine on motor activity and attention deficit. Interestingly, while no changes in the motor activity measurements were observed before and after caffeine administration, a significant improvement in the attention deficit of the 6-OHDA lesioned rats was achieved after caffeine treatment. Thus, our results led us to hypothesize that caffeine might be useful to manage the attention deficit during the prepubertal period of ADHD.
Assuntos
Transtorno do Deficit de Atenção com Hiperatividade/tratamento farmacológico , Atenção/efeitos dos fármacos , Cafeína/uso terapêutico , Estimulantes do Sistema Nervoso Central/uso terapêutico , Animais , Transtorno do Deficit de Atenção com Hiperatividade/induzido quimicamente , Cafeína/farmacologia , Estimulantes do Sistema Nervoso Central/farmacologia , Modelos Animais de Doenças , Atividade Motora/efeitos dos fármacos , Oxidopamina/farmacologia , RatosRESUMO
Una complicación o incidente como las caídas puede tener motivo en múltiples factores como ser efectos colaterales de ansiolíticos, antiarrítmicos, vasodilatadores, betabloqueantes, antidepresivos, etc., y la interacción entre los mismos. Además pueden relacionanarse con la edad, el sexo, la debilidad y la osteopenia más frecuentes en mujeres que en hombres. El riesgo de caídas se encuentra relacionado con el estado del paciente y con los factores ambientales y cambios en el metabolismo y equilibrio electrolítico por edad avanzada. Otro factor importante y objeto de estudio en este trabajo es la calidad de la atención de enfermería ya que la caída es un indicador reflejo de la misma. Contenido: Formulación del problema. Estado actual de conocimientos sobre el tema a investigar. Definición operacional de términos. Población e instrumento de recolección de datos. Listado secuencial de las actividades. Campo de aplicación. Recursos humanos y materiales. Presupuesto
Assuntos
Humanos , Idoso , Acidentes , Acidentes por Quedas , Argentina , Cuidados de Enfermagem , Pesquisa/métodos , Coleta de Dados/métodos , Pacientes InternadosRESUMO
Una complicación o incidente como las caídas puede tener motivo en múltiples factores como ser efectos colaterales de ansiolíticos, antiarrítmicos, vasodilatadores, betabloqueantes, antidepresivos, etc., y la interacción entre los mismos. Además pueden relacionanarse con la edad, el sexo, la debilidad y la osteopenia más frecuentes en mujeres que en hombres. El riesgo de caídas se encuentra relacionado con el estado del paciente y con los factores ambientales y cambios en el metabolismo y equilibrio electrolítico por edad avanzada. Otro factor importante y objeto de estudio en este trabajo es la calidad de la atención de enfermería ya que la caída es un indicador reflejo de la misma. Contenido: Formulación del problema. Estado actual de conocimientos sobre el tema a investigar. Definición operacional de términos. Población e instrumento de recolección de datos. Listado secuencial de las actividades. Campo de aplicación. Recursos humanos y materiales. Presupuesto